Application | Comment | Organism |
---|---|---|
medicine | the enzyme has therapeutic potential in peptide-based cardiovascular drug development | Brevibacillus brevis |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-bromophenacyl bromide | 78.5% residual activity at 2 mM | Brevibacillus brevis | |
disodium-EDTA | 21.1% residual activity at 4 mM | Brevibacillus brevis | |
dithiothreitol | 92.8% residual activity at 4 mM | Brevibacillus brevis | |
iodoacetamide | 49.9% residual activity at 4 mM | Brevibacillus brevis | |
N-4-tosyl-phenylalanyl chloromethyl ketone | 16.5% residual activity at 0.1 mM | Brevibacillus brevis | |
Nalpha-tosyl-L-lysine chloromethylketone | 51.5% residual activity at 0.1 mM | Brevibacillus brevis | |
phenylmethylsulfonyl fluoride | 52.9% residual activity at 2 mM | Brevibacillus brevis |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
55000 | - |
1 * 55000, SDS-PAGE | Brevibacillus brevis |
56043 | - |
1 * 56043, MALDI-TOF mass spectrometry | Brevibacillus brevis |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
Fibrin + H2O | Brevibacillus brevis | - |
? | - |
? | |
Fibrin + H2O | Brevibacillus brevis FF02B | - |
? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Brevibacillus brevis | - |
- |
- |
Brevibacillus brevis FF02B | - |
- |
- |
Purification (Comment) | Organism |
---|---|
ammonium sulfate precipitation, Hi Prep phenyl column chromatography, and Superdex 75 gel filtration | Brevibacillus brevis |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
additional information | - |
the enzyme shows specific activity of 5.2 units/mg (cell free crude extract) and 64.9 units/mg (after 12.4 fold purification). One unit is defined as microgram of L-tyrosine equivalent liberated per ml per min after 30 min incubation at 37°C | Brevibacillus brevis |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
bovine plasma fibrinogen + H2O | marginal hydrolytic activity | Brevibacillus brevis | ? | - |
? | |
bovine plasma fibrinogen + H2O | marginal hydrolytic activity | Brevibacillus brevis FF02B | ? | - |
? | |
bovine serum gamma-globulin + H2O | marginal hydrolytic activity | Brevibacillus brevis | ? | - |
? | |
casein + H2O | marginal hydrolytic activity | Brevibacillus brevis | ? | - |
? | |
casein + H2O | marginal hydrolytic activity | Brevibacillus brevis FF02B | ? | - |
? | |
Fibrin + H2O | - |
Brevibacillus brevis | ? | - |
? | |
Fibrin + H2O | - |
Brevibacillus brevis FF02B | ? | - |
? | |
additional information | no activity with plasminogen, N-benzoyl-Pro-Phe-Arg-4-nitroanilide, N-benzoyl-Ile-Glu-Gly-Arg-4-nitroanilide, N-(4-tosyl)-Gly-Pro-Arg-4-nitroanilide, and bovine serum albumin | Brevibacillus brevis | ? | - |
? | |
additional information | no activity with plasminogen, N-benzoyl-Pro-Phe-Arg-4-nitroanilide, N-benzoyl-Ile-Glu-Gly-Arg-4-nitroanilide, N-(4-tosyl)-Gly-Pro-Arg-4-nitroanilide, and bovine serum albumin | Brevibacillus brevis FF02B | ? | - |
? | |
Nalpha-benzoyl-DL-arginine-4-nitroanilide + H2O | marginal hydrolytic activity | Brevibacillus brevis | Nalpha-benzoyl-DL-arginine + 4-nitroaniline | - |
? | |
Nalpha-benzoyl-DL-arginine-4-nitroanilide + H2O | marginal hydrolytic activity | Brevibacillus brevis FF02B | Nalpha-benzoyl-DL-arginine + 4-nitroaniline | - |
? |
Subunits | Comment | Organism |
---|---|---|
monomer | 1 * 55000, SDS-PAGE | Brevibacillus brevis |
monomer | 1 * 56043, MALDI-TOF mass spectrometry | Brevibacillus brevis |
Synonyms | Comment | Organism |
---|---|---|
brevithrombolase | - |
Brevibacillus brevis |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
- |
Brevibacillus brevis |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.4 | - |
- |
Brevibacillus brevis |